Belgium's Ablynx in Merck cancer research tie-up: firm

February 3, 2014

Belgian biotechnology company Ablynx said on Monday it has signed a cancer research cooperation accord with US pharmaceuticals giant Merck & Co. which could be worth up to 1.7 billion euros ($2.3 billion).

The contract, to identify proteins which may lead to cancer immunotherapy treatments, involves an initial payment of 20 million euros plus 10.7 million euros for the three-year research programme.

Subsequent royalties on sales could lead to payment of 1.7 billion euros, Ablynx said in a statement.

Merck will be responsible for development, manufacture and say of any treatments generated by the research.

Immunotherapy treatments aim to boost the body's own immune response so as to fight .

Explore further: German drug maker Merck ups forecast for 2013

Related Stories

German drug maker Merck ups forecast for 2013

November 14, 2013
German chemicals and pharmaceuticals giant Merck KGaA said Thursday it is raising its full-year operating profit forecast thanks to improving sales and positive cost-cutting effects.

Higher prices for MS drug help drug firm Merck

May 14, 2013
(AP)—Higher prices for its multiple sclerosis drug Rebif helped German pharmaceutical and high-tech materials company Merck KGaA post a 54 percent rise in first-quarter profit.

Recommended for you

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

Breast cancer gene does not boost risk of death: study

January 12, 2018
Young women with the BRCA gene mutation that prompted actress Angelina Jolie's pre-emptive and much-publicised double mastectomy are not more likely to die after a breast cancer diagnosis, scientists said Friday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.